{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:05:09Z","timestamp":1766127909791,"version":"3.48.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72204073"],"award-info":[{"award-number":["72204073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Medical and Health Science and Technology","award":["2023KY491"],"award-info":[{"award-number":["2023KY491"]}]},{"name":"Science and Technology Projects in the Zhejiang Province Department of Education","award":["Y202146979"],"award-info":[{"award-number":["Y202146979"]}]},{"name":"Science and Technology Projects in the Zhejiang Province Department of Education","award":["Y202249053"],"award-info":[{"award-number":["Y202249053"]}]},{"name":"Shaoxing Health Science and Technology Plan Project","award":["KY2022066"],"award-info":[{"award-number":["KY2022066"]}]},{"name":"Zhejiang Medical Association Clinical Medicine Project","award":["2022ZYC-Z37"],"award-info":[{"award-number":["2022ZYC-Z37"]}]},{"name":"Zhejiang Medical Association Clinical Medicine Project","award":["2023ZYC-A55"],"award-info":[{"award-number":["2023ZYC-A55"]}]},{"name":"the Ministry of Education Industry-University Cooperative Education Project","award":["22087043124451"],"award-info":[{"award-number":["22087043124451"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07614-9","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T03:02:27Z","timestamp":1722999747000},"page":"1481-1488","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Levosimendan: A New Therapeutical Strategy in Patients with Renal Insufficiency"],"prefix":"10.1007","volume":"39","author":[{"given":"Xinwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengkai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanna","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nannan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiana","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-0787","authenticated-orcid":false,"given":"Yongping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6067-5029","authenticated-orcid":false,"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"7614_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s0014-2999(97)01108-4","volume":"333","author":"H Yokoshiki","year":"1997","unstructured":"Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol. 1997;333:249\u201359. https:\/\/doi.org\/10.1016\/s0014-2999(97)01108-4.","journal-title":"Eur J Pharmacol"},{"key":"7614_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1211\/0022357001773715","volume":"52","author":"J Pataricza","year":"2000","unstructured":"Pataricza J, H\u00f5hn J, Petri A, Balogh A, Papp JG. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52:213\u20137. https:\/\/doi.org\/10.1211\/0022357001773715.","journal-title":"J Pharm Pharmacol"},{"key":"7614_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13613-021-00810-y","volume":"11","author":"CC Chan","year":"2021","unstructured":"Chan CC, Lee KT, Ho WJ, Chan YH, Chu PH. Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study. Ann Intensive Care. 2021;11:27. https:\/\/doi.org\/10.1186\/s13613-021-00810-y.","journal-title":"Ann Intensive Care"},{"key":"7614_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10557-018-6838-2","volume":"32","author":"S Bouchez","year":"2018","unstructured":"Bouchez S, Fedele F, Giannakoulas G, et al. Levosimendan in acute and advanced heart failure: an expert perspective on posology and therapeutic application. Cardiovasc Drugs Ther. 2018;32:617\u201324. https:\/\/doi.org\/10.1007\/s10557-018-6838-2.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7614_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/eht386.","journal-title":"Eur Heart J"},{"key":"7614_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13613-023-01164-3","volume":"13","author":"B Cholley","year":"2023","unstructured":"Cholley B, Bojan M, Guillon B, et al. Overview of the current use of levosimendan in France: a prospective observational cohort study. Ann Intensive Care. 2023;13:69. https:\/\/doi.org\/10.1186\/s13613-023-01164-3.","journal-title":"Ann Intensive Care"},{"key":"7614_CR7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1080\/14740338.2021.1986483","volume":"20","author":"PM Honore","year":"2021","unstructured":"Honore PM, Redant S, Moorthamers S, et al. What should clinicians know about the renal effect and the mechanism of action of levosimendan? Expert Opin Drug Saf. 2021;20:1459\u201361. https:\/\/doi.org\/10.1080\/14740338.2021.1986483.","journal-title":"Expert Opin Drug Saf"},{"key":"7614_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejps.2007.08.003","volume":"32","author":"J Puttonen","year":"2007","unstructured":"Puttonen J, Laine T, Ramela M, et al. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. Eur J Pharm Sci\u202f: Off J Eur Fed Pharma Sci. 2007;32:271\u20137. https:\/\/doi.org\/10.1016\/j.ejps.2007.08.003.","journal-title":"Eur J Pharm Sci : Off J Eur Fed Pharma Sci"},{"key":"7614_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00003088-200746030-00004","volume":"46","author":"J Puttonen","year":"2007","unstructured":"Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46:235\u201346. https:\/\/doi.org\/10.2165\/00003088-200746030-00004.","journal-title":"Clin Pharmacokinet"},{"key":"7614_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-007-6070-y","volume":"21","author":"K Damman","year":"2007","unstructured":"Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to \u201cLevosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al.\u201d Cardiovasc Drugs Ther. 2007;21:403\u20134. https:\/\/doi.org\/10.1007\/s10557-007-6070-y.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7614_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1186\/s13054-019-2642-z","volume":"23","author":"PM Honore","year":"2019","unstructured":"Honore PM, Gutierrez LB, Redant S, Kaefer K, Gallerani A, De Bels D. How levosimendan can improve renal function? Crit Care. 2019;23:331. https:\/\/doi.org\/10.1186\/s13054-019-2642-z.","journal-title":"Crit Care"},{"key":"7614_CR12","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1097\/CCM.0b013e3182963fdc","volume":"41","author":"AK Gamilla-Crudo","year":"2013","unstructured":"Gamilla-Crudo AK, Kadambi PV, Prough DS. Test driving levosimendan as the new \u201ckidney protector\u201d: first impressions. Crit Care Med. 2013;41:2445\u20136. https:\/\/doi.org\/10.1097\/CCM.0b013e3182963fdc.","journal-title":"Crit Care Med"},{"key":"7614_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40265-022-01833-w","volume":"83","author":"D Masarone","year":"2023","unstructured":"Masarone D, Kittleson M, Pollesello P, Tedford RJ, Pacileo G. Use of levosimendan in patients with pulmonary hypertension: what is the current evidence? Drugs. 2023;83:195\u2013201. https:\/\/doi.org\/10.1007\/s40265-022-01833-w.","journal-title":"Drugs"},{"key":"7614_CR14","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1002\/ehf2.13669","volume":"8","author":"D Burkhoff","year":"2021","unstructured":"Burkhoff D, Rich S, Pollesello P, Papp Z. Levosimendan-induced venodilation is mediated by opening of potassium channels. ESC heart failure. 2021;8:4454\u201364. https:\/\/doi.org\/10.1002\/ehf2.13669.","journal-title":"ESC heart failure"},{"key":"7614_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1124\/jpet.112.193961","volume":"342","author":"E Grossini","year":"2012","unstructured":"Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia\/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342:376\u201388. https:\/\/doi.org\/10.1124\/jpet.112.193961.","journal-title":"J Pharmacol Exp Ther"},{"key":"7614_CR16","doi-asserted-by":"publisher","first-page":"F1453","DOI":"10.1152\/ajprenal.00485.2005","volume":"290","author":"RA Zager","year":"2006","unstructured":"Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol. 2006;290:F1453\u201362. https:\/\/doi.org\/10.1152\/ajprenal.00485.2005.","journal-title":"Am J Physiol Renal Physiol"},{"key":"7614_CR17","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.5114\/aoms\/111373","volume":"17","author":"MK Tawfik","year":"2021","unstructured":"Tawfik MK, Makary S, Keshawy MM. Upregulation of antioxidant nuclear factor erythroid 2-related factor 2 and its dependent genes associated with enhancing renal ischemic preconditioning renoprotection using levosimendan and cilostazol in an ischemia\/reperfusion rat model. Arch Med Sci\u202f: AMS. 2021;17:1783\u201396. https:\/\/doi.org\/10.5114\/aoms\/111373.","journal-title":"Arch Med Sci : AMS"},{"key":"7614_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1510\/icvts.2007.161356","volume":"7","author":"N Yakut","year":"2008","unstructured":"Yakut N, Yasa H, Bahriye Lafci B, et al. The influence of levosimendan and iloprost on renal ischemia-reperfusion: an experimental study. Interact Cardiovasc Thorac Surg. 2008;7:235\u20139. https:\/\/doi.org\/10.1510\/icvts.2007.161356.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"7614_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/0748233712451773","volume":"30","author":"I Gecit","year":"2014","unstructured":"Gecit I, Kavak S, Y\u00fcksel MB, et al. Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats. Toxicol Ind Health. 2014;30:47\u201351. https:\/\/doi.org\/10.1177\/0748233712451773.","journal-title":"Toxicol Ind Health"},{"key":"7614_CR20","doi-asserted-by":"publisher","first-page":"e0163675","DOI":"10.1371\/journal.pone.0163675","volume":"11","author":"P Onody","year":"2016","unstructured":"Onody P, Aranyi P, Turoczi Z, et al. Levosimendan administration in limb ischemia: multicomponent signaling serving kidney protection. PLoS ONE. 2016;11:e0163675. https:\/\/doi.org\/10.1371\/journal.pone.0163675.","journal-title":"PLoS ONE"},{"key":"7614_CR21","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/2211-5463.13227","volume":"11","author":"L Tian","year":"2021","unstructured":"Tian L, Wang S, Zhao L, et al. Renoprotective effects of levosimendan on acute kidney injury following cardiac arrest via anti-inflammation, anti-apoptosis, and ERK activation. FEBS Open Bio. 2021;11:2236\u201344. https:\/\/doi.org\/10.1002\/2211-5463.13227.","journal-title":"FEBS Open Bio"},{"key":"7614_CR22","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.21037\/tau-21-443","volume":"10","author":"L Zhao","year":"2021","unstructured":"Zhao L, Tian L, Wang S, Yang W, Lu X, Zhu C. Levosimendan in rats decreases acute kidney injury after cardiopulmonary resuscitation by improving mitochondrial dysfunction. Transl Androl Urol. 2021;10:3010\u201320. https:\/\/doi.org\/10.21037\/tau-21-443.","journal-title":"Transl Androl Urol"},{"key":"7614_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10557-007-6066-7","volume":"21","author":"MB Yilmaz","year":"2007","unstructured":"Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21:431\u20135. https:\/\/doi.org\/10.1007\/s10557-007-6066-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7614_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/1755-5922.12001","volume":"31","author":"ZQ Hou","year":"2013","unstructured":"Hou ZQ, Sun ZX, Su CY, et al. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther. 2013;31:108\u201314. https:\/\/doi.org\/10.1111\/1755-5922.12001.","journal-title":"Cardiovasc Ther"},{"key":"7614_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ejhf.9","volume":"16","author":"F Fedele","year":"2014","unstructured":"Fedele F, Bruno N, Brasolin B, Caira C, D\u2019Ambrosi A, Mancone M. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16:281\u20138. https:\/\/doi.org\/10.1002\/ejhf.9.","journal-title":"Eur J Heart Fail"},{"key":"7614_CR26","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1053\/j.jvca.2018.02.039","volume":"32","author":"A Zangrillo","year":"2018","unstructured":"Zangrillo A, Alvaro G, Belletti A, et al. Effect of levosimendan on renal outcome in cardiac surgery patients with chronic kidney disease and perioperative cardiovascular dysfunction: a substudy of a multicenter randomized trial. J Cardiothorac Vasc Anesth. 2018;32:2152\u20139. https:\/\/doi.org\/10.1053\/j.jvca.2018.02.039.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"7614_CR27","doi-asserted-by":"publisher","first-page":"986039","DOI":"10.3389\/fcvm.2022.986039","volume":"9","author":"H Zhang","year":"2022","unstructured":"Zhang H, Jiang L, Fu R, et al. Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: a perspective, multi-center, real-world registry. Front Cardiovasc Med. 2022;9:986039. https:\/\/doi.org\/10.3389\/fcvm.2022.986039.","journal-title":"Front Cardiovasc Med"},{"key":"7614_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1590\/s0066-782x2012005000048","volume":"98","author":"A Zorlu","year":"2012","unstructured":"Zorlu A, Y\u00fccel H, Yontar OC, et al. Effect of levosimendan in patients with severe systolic heart failure and worsening renal function. Arq Bras Cardiol. 2012;98:537\u201343. https:\/\/doi.org\/10.1590\/s0066-782x2012005000048.","journal-title":"Arq Bras Cardiol"},{"key":"7614_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/FJC.0000000000001255","volume":"79","author":"X Cui","year":"2022","unstructured":"Cui X, Wang Z, Dong X, et al. Comparative effectiveness and safety of milrinone and levosimendan as initial inotrope therapy in patients with acute heart failure with renal dysfunction. J Cardiovasc Pharmacol. 2022;79:781\u201390. https:\/\/doi.org\/10.1097\/FJC.0000000000001255.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7614_CR30","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1097\/CCM.0b013e31828e946a","volume":"41","author":"G Bragadottir","year":"2013","unstructured":"Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41:2328\u201335. https:\/\/doi.org\/10.1097\/CCM.0b013e31828e946a.","journal-title":"Crit Care Med"},{"key":"7614_CR31","doi-asserted-by":"publisher","first-page":"E230","DOI":"10.1532\/hsf.1426","volume":"19","author":"H Atalay","year":"2016","unstructured":"Atalay H, Temizturk Z, Altinsoy HB, et al. Levosimendan use increases cardiac performance after coronary artery bypass grafting in end-stage renal disease patients. Heart Surg Forum. 2016;19:E230\u20136. https:\/\/doi.org\/10.1532\/hsf.1426.","journal-title":"Heart Surg Forum"},{"key":"7614_CR32","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.jvca.2012.01.035","volume":"26","author":"A Ristikankare","year":"2012","unstructured":"Ristikankare A, P\u00f6yhi\u00e4 R, Eriksson H, Valtonen M, Leino K, Salmenper\u00e4 M. Effects of levosimendan on renal function in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth. 2012;26:591\u20135. https:\/\/doi.org\/10.1053\/j.jvca.2012.01.035.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"7614_CR33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2147\/TCRM.S102772","volume":"12","author":"JL Guerrero-Orriach","year":"2016","unstructured":"Guerrero-Orriach JL, Ariza-Villanueva D, Florez-Vela A, et al. Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase. Ther Clin Risk Manag. 2016;12:623\u201330. https:\/\/doi.org\/10.2147\/TCRM.S102772.","journal-title":"Ther Clin Risk Manag"},{"key":"7614_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10877-016-9827-7","volume":"31","author":"JL Guerrero Orriach","year":"2017","unstructured":"Guerrero Orriach JL, Gal\u00e1n Ortega M, Ram\u00edrez Fernandez A, et al. Assessing the effect of preoperative levosimendan on renal function in patients with right ventricular dysfunction. J Clin Monit Comput. 2017;31:227\u201330. https:\/\/doi.org\/10.1007\/s10877-016-9827-7.","journal-title":"J Clin Monit Comput"},{"key":"7614_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13019-014-0167-8","volume":"9","author":"F Balzer","year":"2014","unstructured":"Balzer F, Treskatsch S, Spies C, et al. Early administration of levosimendan is associated with improved kidney function after cardiac surgery - a retrospective analysis. J Cardiothorac Surg. 2014;9:167. https:\/\/doi.org\/10.1186\/s13019-014-0167-8.","journal-title":"J Cardiothorac Surg"},{"issue":"859","key":"7614_CR36","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jcrc.2015.03.008","volume":"30","author":"S Treskatsch","year":"2015","unstructured":"Treskatsch S, Balzer F, Geyer T, et al. Early levosimendan administration is associated with decreased mortality after cardiac surgery. J Crit Care. 2015;30(859):e1-6. https:\/\/doi.org\/10.1016\/j.jcrc.2015.03.008.","journal-title":"J Crit Care"},{"key":"7614_CR37","doi-asserted-by":"publisher","first-page":"1213696","DOI":"10.3389\/fcvm.2023.1213696","volume":"10","author":"F Schiefenh\u00f6vel","year":"2023","unstructured":"Schiefenh\u00f6vel F, Berger C, Penkova L, et al. Influence of timing of levosimendan administration on outcomes in cardiac surgery. Front Cardiovasc Med. 2023;10:1213696. https:\/\/doi.org\/10.3389\/fcvm.2023.1213696.","journal-title":"Front Cardiovasc Med"},{"key":"7614_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12871-022-01663-z","volume":"22","author":"ZS Li","year":"2022","unstructured":"Li ZS, Wang K, Pan T, et al. The evaluation of levosimendan in patients with acute myocardial infarction related ventricular septal rupture undergoing cardiac surgery: a prospective observational cohort study with propensity score analysis. BMC Anesthesiol. 2022;22:135. https:\/\/doi.org\/10.1186\/s12871-022-01663-z.","journal-title":"BMC Anesthesiol"},{"key":"7614_CR39","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/ctr.12424","volume":"28","author":"I Knezevic","year":"2014","unstructured":"Knezevic I, Poglajen G, Hrovat E, Oman A, Pintar T, Wu JC, et al. The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. Clin Transplant. 2014;28:1105\u201311. https:\/\/doi.org\/10.1111\/ctr.12424.","journal-title":"Clin Transplant"},{"key":"7614_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cardfail.2007.03.005","volume":"13","author":"G Zemljic","year":"2007","unstructured":"Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Cardiac Fail. 2007;13:417\u201321. https:\/\/doi.org\/10.1016\/j.cardfail.2007.03.005.","journal-title":"J Cardiac Fail"},{"key":"7614_CR41","doi-asserted-by":"publisher","unstructured":"M'Pembele R, Roth S, Stroda A, et al. Risk factors for acute kidney injury requiring renal replacement therapy after orthotopic heart transplantation in patients with preserved renal function. Journal of clinical medicine. 2021;10. https:\/\/doi.org\/10.3390\/jcm10184117.","DOI":"10.3390\/jcm10184117"},{"key":"7614_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12871-019-0888-2","volume":"19","author":"JL Guerrero Orriach","year":"2019","unstructured":"Guerrero Orriach JL, Navarro Arce I, Hernandez Rodriguez P, et al. Preservation of renal function in cardiac surgery patients with low cardiac output syndrome: levosimendan vs beta agonists. BMC Anesthesiol. 2019;19:212. https:\/\/doi.org\/10.1186\/s12871-019-0888-2.","journal-title":"BMC Anesthesiol"},{"key":"7614_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13054-021-03628-z","volume":"25","author":"M Thol\u00e9n","year":"2021","unstructured":"Thol\u00e9n M, Ricksten SE, Lannemyr L. Effects of levosimendan on renal blood flow and glomerular filtration in patients with acute kidney injury after cardiac surgery: a double blind, randomized placebo-controlled study. Critical care (London, England). 2021;25:207. https:\/\/doi.org\/10.1186\/s13054-021-03628-z.","journal-title":"Critical care (London, England)"},{"key":"7614_CR44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3389\/fphar.2020.01331","volume":"11","author":"JL Guerrero-Orriach","year":"2020","unstructured":"Guerrero-Orriach JL, Malo-Manso A, Ramirez-Aliaga M, et al. Renal and neurologic benefit of levosimendan vs dobutamine in patients with low cardiac output syndrome after cardiac surgery: clinical trial FIM-BGC-2014-01. Front Pharmacol. 2020;11:1331. https:\/\/doi.org\/10.3389\/fphar.2020.01331.","journal-title":"Front Pharmacol"},{"key":"7614_CR45","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1616218","volume":"376","author":"RH Mehta","year":"2017","unstructured":"Mehta RH, Leimberger JD, van Diepen S, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med. 2017;376:2032\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1616218.","journal-title":"N Engl J Med"},{"key":"7614_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ahj.2020.10.066","volume":"231","author":"OK Jawitz","year":"2021","unstructured":"Jawitz OK, Stebbins AS, Raman V, et al. Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: insights from the LEVO-CTS trial. Am Heart J. 2021;231:18\u201324. https:\/\/doi.org\/10.1016\/j.ahj.2020.10.066.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07614-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:00:55Z","timestamp":1766127655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7614"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07614-9","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"28 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}